Client News

Okyo Pharma Limited: PDMR Dealing
Home / Client News / Okyo Pharma Limited: PDMR Dealing

London and Boston, MA, January 27, 2022 – OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 200,000 ordinary shares of no par value in the market at prices between 5p and 5.5p per share.

The acquisitions increase Mr Cerrone’s beneficial interests in the capital of the Company from 52.64% to 52.66%.


If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.


Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

Share This